Posted 7th September 2021 by Nicholas Noakes
There has been a rapid acceleration of skin microbiome research. Today about 5% of all microbiome clinical studies and 16% of all probiotic products online are dermatology related. Meanwhile, skin probiotics are growing eight times faster than any other probiotic supplement. In clinical cosmetic studies, the microbiome is the fourth largest category.
Posted 31st August 2021 by Nicholas Noakes
“Digital pathology has reached the point where if you don’t have digitized slides, you will not be able to do six out of ten things that other pathologists can do today.”
Dr. Anil Parwani
Posted 30th July 2021 by Nicholas Noakes
George Makar spoke at the Global NASH Congress. He gave a regulatory perspective on Drug Development for NASH with Fibrosis. The views were his own. In part one, we explore expedited programs.
Posted 22nd July 2021 by Nicholas Noakes
Speaking at the recent Microbiome R&D and Business Collaboration Forum, Anthony Hannan explored research using mouse models for brain disorders, particularly in Huntington’s disease (HD), schizophrenia, depression, and anxiety disorders. He also examined the role of gene-environment interactions involving mental activity, physical activity, stressors, and diet.
Posted 29th June 2021 by Nicholas Noakes
Genevieve Boland, speaking at the Research & Technology Series, described the translational research conducted at her laboratory. Using tumour and blood samples from patients before treatment, at meaningful clinical changes, progression, and post-mortem she, and her team are trying to understand the biology of Melanoma to treat patients better.
Posted 25th May 2021 by Nicholas Noakes
Andrew Evans, speaking at the Digital Pathology & AI Congress USA, described new guidelines he helped to draft for validating whole-slide-imaging for diagnostic purposes. First published in 2013 the guidelines were designed to address the fundamental question, “what needs to be done to validate a whole slide imaging for diagnostic use?”. The review producing the new guidelines was published in May 2021.
Posted 30th April 2021 by Nicholas Noakes
Professor Andrew Martin, UCL, speaking at the 4th Global Pharma R&D AI, Data Science and Informatics Summit, described using the abYsis database and workbench for drug discovery. He showed how it is possible to explore an annotate antibody sequence and structure, including comparisons with observed residue distributions. The database can also aid with humanization by making sequences more human and library design.
Posted 30th March 2021 by Nicholas Noakes
Predicting the outcome of cancer can help the clinical decision-making process related to a patient’s treatment. The potential for Artificial Intelligence (AI) to support this was a key facet of the final keynote speech to the online 7th Digital Pathology and AI Congress: Europe, by Johan Lundin, Research Director at the Institute for Molecular Medicine Finland (FIMM) at the University of Helsinki and Professor of Medical Technology at Karolinska Institutet.